Seguir
Djoke Hendriks
Djoke Hendriks
PhD student, Translational Surgical Oncology, University Medical Center Groningen
Dirección de correo verificada de umcg.nl
Título
Citado por
Citado por
Año
Designing and producing modified, new-to-nature peptides with antimicrobial activity by use of a combination of various lantibiotic modification enzymes
AJ van Heel, D Mu, M Montalbán-López, D Hendriks, OP Kuipers
ACS synthetic biology 2 (7), 397-404, 2013
862013
Discovery, production and modification of five novel lantibiotics using the promiscuous nisin modification machinery
AJ van Heel, TG Kloosterman, M Montalban-Lopez, J Deng, A Plat, ...
ACS synthetic biology 5 (10), 1146-1154, 2016
692016
Antibody-based cancer therapy: successful agents and novel approaches
D Hendriks, G Choi, M de Bruyn, VR Wiersma, E Bremer
International review of cell and molecular biology 331, 289-383, 2017
422017
A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
I Koopmans, D Hendriks, DF Samplonius, RJ van Ginkel, S Heskamp, ...
Oncoimmunology 7 (8), e1466016, 2018
372018
Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
D Hendriks, Y He, I Koopmans, VR Wiersma, RJ van Ginkel, ...
Oncoimmunology 5 (8), e1202390, 2016
362016
C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity
VR Wiersma, M de Bruyn, C Shi, MJM Gooden, MCA Wouters, ...
MAbs 7 (2), 321-330, 2015
272015
Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal …
NJ Weston-Bell, D Hendriks, G Sugiyarto, NA Bos, HC Kluin-Nelemans, ...
Leukemia 27 (1), 241-245, 2013
262013
Melanoma-directed activation of apoptosis using a novel bispecific antibody directed at MCSP and TRAIL receptor 2/Death Receptor 5
Y He, D Hendriks, R van Ginkel, D Samplonius, E Bremer, W Helfrich
Journal of Investigative Dermatology 136, 541-4, 2016
242016
Hairy cell leukemia cell lines display B-cell receptor signals characteristic of primary tumor cells but lack the signature BRAF mutation to reveal unrepresentative origins
N Weston-Bell, D Hendriks, G Sugiyarto, N Bos, J Kluin-Nelemans, ...
HAEMATOLOGICA 97, 124-124, 2012
12012
Novel antibody-based drugs for PD-L1 and TRAIL-R targeted cancer immunotherapy
D Hendriks
Rijksuniversiteit Groningen, 2017
2017
First and shared first author publications
AJ van Heel, T Kloosterman, M Montalbán-López, D Jingjing, A Plat, ...
Prediction, production and characterization of post-translationally modified …, 2016
2016
Melanoma-directed activation of apoptosis using a novel bispecific antibody directed against MCSP and Death Receptor 5
Y He, D Hendriks, R Van Ginkel, D Samplonius, E Bremer, W Helfrich
European Journal of Cancer 1 (61), S119, 2016
2016
A novel bispecific antibody for EGFR-directed PD-1/PD-L1 immune checkpoint inhibition
I Koopmans, D Hendriks, DF Samplonius, E Bremer, W Helfrich
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–13